Babesiosis Data Readout Today As 60 Degrees Pharmaceuticals Shares Climb
60 Degrees Pharmaceuticals (SXTP) shares rose 18% ahead of interim data release from its Phase 2 study of tafenoquine for severe babesiosis. The study, involving at least 24 patients, evaluates tafenoquine with standard care. No FDA-approved treatment exists for babesiosis, a tick-borne disease. SXTP's stock traded between $0.84 and $8.62 in the past year, closing Monday at $1.44.
How this was made
The 30-second read
Why it matters
The interim readout is the first data point for this indication and has already moved the stock 18% in pre‑market trading.
Market read
The announcement creates a short‑term trading catalyst for SXTP, with potential upside if the interim data are favorable.
What to watch
Regulatory timeline for tafenoquine in babesiosis and competition from other anti‑parasitic candidates.
Background
60 Degrees Pharmaceuticals (SXTP) is developing tafenoquine, currently marketed for malaria, as a treatment for severe babesiosis, a disease with no approved therapy.
Ticker impact
The article announces that 60 Degrees Pharmaceuticals will release interim Phase 2 data on tafenoquine for severe babesiosis today, a new catalyst for the stock.
potential upside pressure as investors price in positive interim data; downside risk if data disappoint.
No data have been released yet, but the market has already moved 18% on the announcement, indicating sensitivity to the outcome.
Market effects
Positive babesia trial data could boost interest in anti‑parasitic biotech sector.
Limited to U.S. biotech investors; no broad regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
If interim data are inconclusive, the stock could face a sharp correction after the hype fades.
Key entities
- ExpertPeter J. Krause, M.D.
Key Opinion Leader from Yale School of Public Health participating in the webinar.
- ExpertEdouard Vannier, Ph.D.
Key Opinion Leader from Tufts University School of Medicine participating in the webinar.
